| |
| Trade Name | TAXUS EXPRESS2 PACLITAXEL-ELUTING CORONARY STENT SYSTEM (MONORAIL AND OVER-THE-WIRE) |
| Classification Name | coronary drug-eluting stent |
| Generic Name | intravascular stent with delivery system |
| Applicant | BOSTON SCIENTIFIC |
| PMA Number | P030025 |
| Supplement Number | S086 |
| Date Received | 03/08/2010 |
| Decision Date | 02/22/2012 |
| Product Code | |
| Docket Number | 12M-0209 |
| Notice Date | 03/07/2012 |
| Advisory Committee |
Cardiovascular |
| Clinical Trials |
NCT00371475
|
| Supplement Type | panel track |
| Supplement Reason | labeling change - indications |
| Expedited Review Granted? | No |
| Combination Product |
Yes
|
| Information About: |
Labeling, Approval Order, Summary of Safety and Effectiveness |
Approval Order Statement Approval to expand the labeled indications for the taxus express2 paclitaxel-eluting coronary stent system. The taxus express2 paclitaxel-eluting coronary stent system is indicated for improving luminal diameter: 1) for the treatment of de novo lesions in native coronary arteries 2. 25 mm to 4. 00 mm in diameter in lesions<= 28 mm in length; 2) in patients undergoing primary angioplasty to treat acute st-segment elevation myocardial infarction, true posterior myocardial infarction, or presumed new left bundle branch block with symptoms of acute myocardial infarction lasting > 20 minutes and < 12 hours in duration; or 3) within bare metal stent restenotic lesions 2. 50 mm to 3. 75 mm in diameter and <= 28 mm in length. |
| Approval Order |
Approval Order
|